We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
-12.49%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+632.23%
AUM
$48.6B
AUM Growth
-$4.2B
(-8%)
Cap. Flow
+$3.6B
Cap. Flow
% of AUM
7.4%
Top 10 Holdings %
Top 10 Hldgs %
10.29%
Holding
4,108
New
835
Increased
963
Reduced
740
Closed
743
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$340M |
| 2 |
Bank of America
BAC
|
+$302M |
| 3 |
Cigna
CI
|
+$294M |
| 4 |
TSMC
TSM
|
+$275M |
| 5 |
Union Pacific
UNP
|
+$256M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Verizon
VZ
|
+$426M |
| 2 |
S&P Global
SPGI
|
+$413M |
| 3 |
Booking.com
BKNG
|
+$264M |
| 4 |
Comcast
CMCSA
|
+$256M |
| 5 |
Teleflex
TFX
|
+$241M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.59% |
| 2 | Financials | 16.96% |
| 3 | Technology | 16.37% |
| 4 | Consumer Discretionary | 9.32% |
| 5 | Industrials | 7.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Cboe Global Markets
CBOE
$29.9B
| $127M | 0.26% |
1,124,540
+257,690
| +30% | +$28.9M |
|
77
Edwards Lifesciences
EW
$51.7B
| $125M | 0.26% |
1,312,902
+883,380
| +206% | +$91.5M |
|
78
General Dynamics
GD
$106B
| $122M | 0.25% |
550,276
+126,090
| +30% | +$29M |
|
79
Illumina
ILMN
$28.4B
| $121M | 0.25% |
677,180
+624,648
| +1,189% | +$160M |
|
80
Expedia Group
EXPE
$37.3B
| $119M | 0.24% |
1,254,996
+66,307
| +6% | +$9.39M |
|
81
Berkshire Hathaway Class B
BRK.B
$1.13T
| $118M | 0.24% |
432,222
-115,957
| -21% | -$36.4M |
|
82
Procter & Gamble
PG
$339B
| $118M | 0.24% |
818,888
-20,108
| -2% | -$3.02M |
|
|
JWN
83
DELISTED
Nordstrom
JWN
| $116M | 0.24% |
5,475,622
+455,243
| +9% | +$11.6M |
|
84
Intel
INTC
$513B
| $115M | 0.24% |
3,075,126
+2,511,749
| +446% | +$109M |
|
85
Insulet
PODD
$9.79B
| $113M | 0.23% |
518,576
+128,304
| +33% | +$29.2M |
|
|
86
Comcast
CMCSA
$90B
| $112M | 0.23% |
2,843,836
-5,961,338
| -68% | -$256M |
|
87
Bio-Rad Laboratories Class A
BIO
$9.42B
| $111M | 0.23% |
224,769
-242,574
| -52% | -$126M |
|
88
Graphic Packaging
GPK
$3.58B
| $111M | 0.23% |
5,396,391
+3,888,531
| +258% | +$82.1M |
|
|
SAIL
89
DELISTED
SailPoint Technologies Holdings, Inc. Common Stock
SAIL
| $110M | 0.23% |
1,760,660
+1,210,391
| +220% | +$74.7M |
|
90
Vertex Pharmaceuticals
VRTX
$126B
| $110M | 0.23% |
+391,152
| New | +$105M |
|
91
NIO
NIO
$11.9B
| $110M | 0.23% |
5,050,307
+4,273,136
| +550% | +$78.4M |
|
92
Option Care Health
OPCH
$3.56B
| $109M | 0.22% |
3,933,573
+1,061,429
| +37% | +$30.2M |
|
93
Entegris
ENTG
$23.2B
| $108M | 0.22% |
1,174,614
-14,597
| -1% | -$1.58M |
|
94
Citizens Financial Group
CFG
$30.6B
| $108M | 0.22% |
3,024,021
-2,934,510
| -49% | -$116M |
|
95
NVIDIA
NVDA
$5.42T
| $108M | 0.22% |
7,097,770
+1,786,780
| +34% | +$33.7M |
|
96
Check Point Software Technologies
CHKP
$13.1B
| $108M | 0.22% |
883,370
+384,578
| +77% | +$49.4M |
|
97
Lumen
LUMN
$6.44B
| $107M | 0.22% |
9,825,397
+3,571,534
| +57% | +$40.1M |
|
98
Axalta
AXTA
$8.17B
| $106M | 0.22% |
4,799,164
+1,340,378
| +39% | +$34.1M |
|
99
PUT
Meta Platforms (Facebook)
META
$1.51T
| $106M | 0.22% |
656,200
+528,000
| +412% | +$102M |
|
100
Marathon Petroleum
MPC
$83.7B
| $106M | 0.22% |
1,286,711
+1,143,587
| +799% | +$107M |
|
Similar funds
Marshall Wace's Q2 2022 Portfolio in Review
As of Q2 2022, Marshall Wace held 4,108 positions worth $48.6B, down 8% from $52.8B the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Marshall Wace deployed $3.6B of net new capital in Q2 2022, opening 835 new positions and adding to 963 existing holdings. Its largest new stake was Eli Lilly: 1,133,393 shares worth $367M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Verizon, an estimated $426M trimmed.
- Marshall Wace's largest Q2 2022 buy was Eli Lilly: 1,133,393 shares worth $367M.
- Marshall Wace added most to Bank of America in Q2 2022, an estimated $302M increase.
- Marshall Wace's biggest Q2 2022 reduction was Verizon, cutting an estimated $426M.
- Marshall Wace fully exited Teleflex in Q2 2022, selling an estimated $241M.
- Marshall Wace's ten largest holdings make up 10% of its $48.6B portfolio in Q2 2022.
- Marshall Wace opened 835 new positions and closed 743 in Q2 2022.
- Marshall Wace's portfolio value fell 8% quarter-over-quarter to $48.6B.
Based on Marshall Wace's 13F filing for Q2 2022, filed 15 Aug 2022.